BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 14569743)

  • 21. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
    Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
    Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia.
    Qazilbash MH; Giralt SA; Champlin RE
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].
    Tachikawa Y; Abe Y; Choi I; Ohtsuka R; Nagasawa E; Shibata K; Nishimura J; Nawata H; Muta K
    Fukuoka Igaku Zasshi; 2005 Nov; 96(11):378-82. PubMed ID: 16502857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
    Resnick IB; Aker M; Shapira MY; Tsirigotis PD; Bitan M; Abdul-Hai A; Samuel S; Ackerstein A; Gesundheit B; Zilberman I; Miron S; Yoffe L; Lvovich A; Slavin S; Or R
    Br J Haematol; 2006 Jun; 133(6):649-54. PubMed ID: 16704442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
    Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
    J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
    Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
    Craddock CF
    Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
    Weisser M; Schleuning M; Ledderose G; Rolf B; Schnittger S; Schoch C; Schwerdtfeger R; Kolb HJ
    Bone Marrow Transplant; 2004 Dec; 34(12):1083-8. PubMed ID: 15489879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results].
    Schmid C; Weisser M; Ledderose G; Stötzer O; Schleuning M; Kolb HJ
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2186-92. PubMed ID: 12397547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; Ruiz-Argüelles A; González-Llano O; Cantú OE; Hernández NE
    Bone Marrow Transplant; 2000 Jan; 25(2):131-3. PubMed ID: 10673669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.